Dexcom Reports Second Quarter 2026 Financial Results
Dexcom reported Q2 2026 revenue of $1.308 billion, up 13% year-over-year, with GAAP operating income increasing 590 basis points to 24.3% of revenue. Management raised FY2026 revenue guidance to $5.18-$5.25 billion and increased targets for non-GAAP gross profit, operating, and EBITDA margins.
Key figures
- Eps
- 0.64
- Revenue
- $1.308 billion
- Guidance
- FY2026 revenue $5.18 - $5.25 billion (approx 11-13% growth); Non-GAAP Gross Margin ~64%; Non-GAAP Operating Margin ~23.5-24%; Adjusted EBITDA Margin ~31.5-32%
- Revenue Yoy
- 13%
- Non gaap eps
- 0.7
- Adjusted ebitda
- $421.3 million
- Cash and liquidity
- $1.95 billion
- Gaap operating income
- $318.3 million
- Gaap operating margin
- 24.3%
- Non gaap operating income
- $328.3 million
- Non gaap operating margin
- 25.1%
- Operating margin expansion bps
- 590
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.